---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007861"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:06:46.375846+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phibro Q3 net income falls 43% to $10.0M; Animal Health sales up 11%

## Summary
- Q3 net sales $245.7M (+3% YoY); net income $10.0M (-43%); diluted EPS $0.25 (-43%); adjusted diluted EPS $0.29 (-13%).
- Animal Health segment net sales +11% to $164.4M; Mineral Nutrition -9% to $62.9M; Performance Products -17% to $18.3M.
- Adjusted EBITDA $27.4M (-2% YoY); free cash flow -$43M trailing twelve months (inventory build of $43M).
- Company reiterates FY2023 guidance: net sales $960M-$1B, adjusted diluted EPS $1.21-$1.31.
- Management notes recessionary pressure in Mineral Nutrition; opened new autogenous vaccine facility in Brazil.

## SEC filing metadata
- accession: 0001558370-23-007861
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/0001558370-23-007861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/pahc-20230503x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007861
- JSON: https://secwatch.observer/filing/0001558370-23-007861.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007861.txt

## Key facts
- Earnings Releases
  PHIBRO ANIMAL HEALTH CORP reported three months ended March 31, 2023 (compared to the three months ended March 31, 2022) results: revenue $245.7 million, net income $10.0 million, EPS diluted EPS of $0.25.
  - Period: three months ended March 31, 2023 (compared to the three months ended March 31, 2022)
  - Revenue: $245.7 million
  - Net income: $10.0 million
  - EPS: diluted EPS of $0.25
  - Result: reported results
  source text: third quarter and year-to-date ended March 31, 2023. ​ Highlights for the three months ended March 31, 2023 (compared to the three months ended March 31, 2022) ​ - Net sales of $245.7 million, an increase of $6.1 million, or 3% - Net income of $10.0 million, a decrease of $7.6 million, or 43% - Diluted EPS of $0.25, a decrease of $0.19, or 43% - Adjusted EBITDA of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/0001558370-23-007861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.